PT  - JOURNAL ARTICLE
AU  - Pham, Thi Mui
AU  - Westerhof, Ilse
AU  - Bootsma, Martin C.J.
AU  - Kretzschmar, Mirjam E.
AU  - Rozhnova, Ganna
AU  - Bruijning-Verhagen, Patricia
TI  - Seasonal patterns of SARS-CoV-2 transmission in secondary schools: a modelling study
AID  - 10.1101/2022.04.21.22273952
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.21.22273952
4099  - http://medrxiv.org/content/early/2022/04/25/2022.04.21.22273952.short
4100  - http://medrxiv.org/content/early/2022/04/25/2022.04.21.22273952.full
AB  - Background The Omicron variant has caused a new wave of SARS-CoV-2 infections worldwide. We explore crucial epidemiological parameters driving seasonal patterns of SARS-CoV-2 transmission in secondary schools and assess various infection control interventions over a 2.5-year time frame.Methods We developed an agent-based model parameterised with data from secondary schools in the Netherlands. We modelled the circulation of Omicron assuming a stable introduction rate of infections and accounted for uncertainty in epidemiological parameters describing virus transmissibility, susceptibility to reinfection, vaccine immune escape, and waning of sterilising immunity. We quantified the SARS-CoV-2 health burden defined as number of symptomatic student days. We further evaluated the cost-benefit (number of prevented infected students per absent student) for reactive quarantine interventions, regular screening using antigen tests, and annual booster vaccinations.Findings Durability of sterilising immunity is a key parameter that governs temporal SARS-CoV-2 transmission patterns in secondary schools. Our model predicts pronounced within-school seasonal patterns with dominant autumn outbreaks and smaller winter outbreaks and a maximum prevalence of 2.9% (95% CI: 0.7%-6.6%) symptomatic students during infection peaks. Regular screening and annual booster vaccination may reduce the health burden up to 15% (95% CI: 1.5%-27.8%) and have a higher cost-benefit ratio than reactive quarantine interventions (reduction: 4.3%; 95% CI: -10.1% to 17.6%).Interpretation Immunity waning will determine the intensity and pattern of SARS-CoV-2 transmission in secondary schools in the medium-term future. If mitigation strategies are needed, screening and annual booster vaccination have the highest cost-benefit by reducing viral transmission with little educational disruption.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGR, IW, and PB were supported by the VERDI project (101045989), funded by the European Union.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used in our study were collected as part of a national implementation programme executed by the ministry of education of the Netherlands. The University Medical Center Utrecht (UMCU) was assigned by the Dutch ministry of education to evaluate the policy. The evaluations have been submitted to the ministery as reports which are all open access (in Dutch) and can be found below. The data from the pilot were published open access after these reports were submitted (1 July 2021) and before we initiated the current study. The UMCU did not collect any data as part of research involving human subjects. * Reports 10 Jun & 7 jul 2021: https://www.rijksoverheid.nl/onderwerpen/voortgezet-onderwijs/documenten/kamerstukken/2021/07/14/onderzoeksrapportages-pilots-inzet-sneltesten-funderend-onderwijs * Report 13 aug 2021: https://www.rijksoverheid.nl/onderwerpen/voortgezet-onderwijs/documenten/kamerstukken/2021/08/13/resultaten-modellering-umcu-vaccinatiegraad-13-augustus * Report 7 sept 2021: https://www.rijksoverheid.nl/documenten/rapporten/2021/09/07/derde-rapport-modellering-sars-cov-2-infecties-in-het-voortgezet-onderwijs The data from the pilot were originally located at: https://github.com/tm-pham/covid19_school_transmission/tree/master/data I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at: https://github.com/tm-pham/covid19_school_transmission/tree/master/data